Assessment of possible drug interactions in patients with psoriasis and associated comorbid medical conditions: An observational study

Reviews on Recent Clinical Trials

Volumn 11, Issue 2, 2016, Pages 128-134

  Sherin, Reena ^a   Udaykumar, Padmaja ^a  

^a FATHER MULLER MEDICAL COLLEGE   (India)

Author keywords

Comorbidities; Drug interaction checker; Drug drug interactions; Monitoring; Psoriasis; Rational drug prescription

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPSORIASIS AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; STATIN (PROTEIN); ANTIINFECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MONITORING; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; DRUG INTERACTION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMORBIDITY; DRUG INTERACTIONS; HUMANS; PROSPECTIVE STUDIES; PSORIASIS;

EID: 84974715593     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887111666160201122532     Document Type: Article

References (49)

1. Swanbeck G, Inerot A, Martinsson T, Wahlström J. A population genetic study of psoriasis. Br J Dermatol 1994; 131: 32-9.
2. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775.
3. Remröd C, Sjöström K, Svensson Å. Subjective stress reactivity in psoriasis-a cross sectional study of associated psychological traits. BMC Dermatol 2015; 15: 6.
4. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441-7.
5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
6. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005; 16: 319-23.
7. Jacobi A, Kupke C, Behzad M, et al. Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. Int J Dermatol 2013; 52: 1081-7.
8. Mahmood M, Malone DC, Skrepnek GH, et al. Potential Drug-Drug Interactions within veterans affairs medical centers. Am J Health Syst Pharm 2007; 64: 1500-5.
9. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: case-control and casecrossover studies. Acta Derm Venereol 2005; 85: 299-303.
10. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000; 1: 159-65.
11. Drug Interaction Checker. Drugs.com. (Accessed May 2015 at http: //www.drugs.com/drug_interactions.html.)
12. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global Epidemiology of Psoriasis: A systematic review of incidence and prevalence. J Investig Dermatol 2013; 133: 377-85.
13. Okhandiar RP, Banerjee BN. Psoriasis in the tropics: An epidemiological survey. J Indian Med Assoc 1963; 41: 550-6.
14. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010; 76: 595-601.
15. Bo K, Thoresen M, Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology 2008; 216: 40-5.
16. Yang YC, Cheng YW, Lai CS, Chen W. Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. J Eur Acad Dermatol Venereol 2007; 21: 643-9.
17. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-6.
18. Kavli G, Førde OH, Arnesen E, Stenvold SE. Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed)1985; 291: 999-1000
19. Chang YT, Chen TJ, Liu PC, et al. Epidemiological study of psoriasis in the National Health Insurance Database in Taiwan. Acta Derm Venereol 2009; 89: 262-6.
20. Seminara NM, Abuabara K, Shin DB, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol 2011; 164: 602-9.
21. Larsson PA, Liden S. Prevalence of skin diseases among adolescents 12-16 years of age. Acta Derm Venereol 1980; 60: 415-23.
22. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-6.
23. Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl 1993; 182: 6-9.
24. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
25. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981; 61: 344-6.
26. Plunkett A, Merlin K, Gill D, Zuo Y, Jolley D, Marks R. The frequency of common nonmalignant skin conditions in adults in central Victoria, Australia. Int J Dermatol 1999; 38: 901-8
27. Hellgren L. Psoriasis: The prevalence in sex, age and occupational groups in total populations in Sweden. morphology, inheritance and association with other skin and rheumatic diseases. Stockholm Almqvist and Wiksell 1967; 15: 44.
28. Cooperative Psoriasis Study Group. Distribution of psoriasis in China: A nationwide screening in 1984. Chinese J Dermatol1986; 19: 253-62.
29. Bedi TR. Psoriasis in North India. Geographical variations. Dermatologica 1977; 155: 310-4.
30. Bedi TR. Clinical profile of psoriasis in North India. Ind J Dermatol Venereol Leprol 1995; 61: 202-5.
31. Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol 1997; 24: 230-4.
32. Handa S, Kaur I. Vitiligo: Clinical findings in 1436 patients. J Dermatol 1999; 26: 653-7.
33. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037-43.
34. Aurangabadkar SJ. Comorbidities in psoriasis. Ind J Dermatol Venereol Leprol 2013; 79: 10-7.
35. Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014; 171: 137-47.
36. Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 2010; 12: 281-7.
37. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-30.
38. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and metaanalysis of observational studies. J Hypertens 2013; 31: 433-42.
39. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.
40. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273: 197-204
41. Saurat JH, Guérin A, Yu AP, et al. High prevalence of potential Drug-Drug Interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010; 220: 128-37.
42. Kulkarni V, Bora SS, Sirisha S, Saji M, Sundaran S. A study on drug-drug interactions through prescription analysis in a South Indian teaching hospital. Ther Adv Drug Saf 2013; 4: 141-6.
43. Kafeel H, Rukh R, Qamar H, et al. Possibility of Drug-Drug Interaction in prescription dispensed by community and hospital pharmacy. Pharmacol Pharm 2014; 5: 401-7.
44. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309-19.
45. Patel PS, Rana DA, Suthar JV, Malhotra SD, Patel VJ. A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital. J Basic Clin Pharm 2014; 5: 44-8.
46. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drugdisease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14: 447-50.
47. Dambro MR, Kallgren MA. Drug interactions in a clinic using COSTAR. Comput Biol Med1988; 18: 31-8.
48. Wu S, Han J, Li WQ, Qureshi AA. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol 2014; 150: 957-63.
49. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606-15.